Technical Articles

Since the innovation of PD-1/PD-L1 inhibitors in tumor treatment, the search for innate immune regulatory targets has become a key direction to overcome the limitations of existing therapies. The CD47 signaling regulatory protein alpha (SIRP alpha, also known as SHPS1) axis is considered a potential target in the field of tumor immunity due to its regulation of the "self recognition" function of innate immune cells such as macrophages.